Smartbax Secures €4.7 Million to Advance Antibiotic Development

Munich-based biotech firm smartbax GmbH has successfully closed a €4.7 million Pre-Series A funding round, led by Anobis Asset and Bayern Kapital. This influx of capital aims to push forward smartbax's novel antibiotic compounds through preclinical stages. The focus is on inhibiting lipopolysaccharide synthesis in Gram-negative bacteria, targeting the increasing threat of multi-drug resistance.

The company's innovative platform centers around small-molecule enzymatic activators that induce bacterial self-digestion, offering a new mode of action. These compounds, which differ from traditional antibiotics, have shown potential in combating resistance in both Gram-positive and Gram-negative bacteria.

smartbax plans to utilize this funding to further develop their distinctive pipeline and bring these novel treatments closer to the market. The round remains open, allowing for further investment opportunities as the company strives to combat antimicrobial resistance.